MedTrace Logo

N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure

NCT00532688 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2007-09-20

No results posted yet for this study

Summary

Treatment with n-acetylcysteine in patients with heart failure and chronic renal failure leads to improvements in vascular function and in renal function.

Conditions

  • Heart Failure, Congestive
  • Kidney Failure, Chronic

Interventions

DRUG

N-acetylcysteine

28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.

Sponsors & Collaborators

  • The Alfred

    collaborator OTHER

  • Bayside Health

    lead OTHER_GOV

Principal Investigators

  • David Kaye, PhD FRACP · Alfred Heart Centre

  • Anthony Camuglia, MBBS · The Alfred

  • Catherine Farrrington · Alfred Heart Centre

  • Jenny Starr · Alfred Heart Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Completion
2008-02-29

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00532688 on ClinicalTrials.gov